Traws Pharma Inc (TRAW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Traws Pharma Inc (TRAW) has a cash flow conversion efficiency ratio of -0.883x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.01 Million) by net assets ($4.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Traws Pharma Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Traws Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Traws Pharma Inc total liabilities for a breakdown of total debt and financial obligations.
Traws Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Traws Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Draper Esprit PLC
LSE:GROW
|
-0.016x |
|
Camplify Holdings Ltd
AU:CHL
|
-0.067x |
|
Alfa Energi Investama Tbk PT
JK:FIRE
|
0.043x |
|
Visgeneer
TWO:4197
|
-0.060x |
|
Hiap Huat Holdings Bhd
KLSE:0160
|
0.130x |
|
B+S Banksysteme Aktiengesellschaft
F:DTD2
|
0.025x |
|
New Bubbleroom Sweden AB
ST:BBROOM
|
0.278x |
|
Noble Helium Ltd
AU:NHE
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Traws Pharma Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Traws Pharma Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Traws Pharma Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-31.63 Million | $-29.79 Million | 0.942x | +156.06% |
| 2023-12-31 | $10.67 Million | $-17.93 Million | -1.680x | -191.93% |
| 2022-12-31 | $28.31 Million | $-16.29 Million | -0.576x | -36.22% |
| 2021-12-31 | $46.12 Million | $-19.49 Million | -0.423x | +88.69% |
| 2020-12-31 | $6.17 Million | $-23.07 Million | -3.737x | -107.62% |
| 2019-12-31 | $11.57 Million | $-20.83 Million | -1.800x | +57.28% |
| 2018-12-31 | $5.39 Million | $-22.70 Million | -4.213x | -292.10% |
| 2017-12-31 | $-10.86 Million | $-23.82 Million | 2.193x | +171.11% |
| 2016-12-31 | $5.13 Million | $-15.81 Million | -3.084x | -6.77% |
| 2015-12-31 | $10.84 Million | $-31.31 Million | -2.889x | -18.37% |
| 2014-12-31 | $23.62 Million | $-57.65 Million | -2.440x | -221.63% |
| 2013-12-31 | $80.90 Million | $-61.38 Million | -0.759x | -7255.60% |
| 2012-12-31 | $-158.31 Million | $1.63 Million | -0.010x | -110.08% |
| 2011-12-31 | $-138.42 Million | $-14.17 Million | 0.102x | -- |
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marbox… Read more